For example, Nimotuzumab, a humanized anti-EGFR monoclonal antibody (mAb) that prevents cancerous cells from proliferating, invading, and metastasizing, was first used to treat an 87-year-old HCC patient. The gene discussed is EGFR; the disease is hepatocellular carcinoma.